19. Lysosomal storage disease
784 clinical trials,   673 drugs   (DrugBank: 101 drugs),   68 drug target genes,   184 drug target pathways

Searched query = "Lysosomal storage disease", "Lysosomal disease", "Gaucher disease", "Niemann-Pick disease", "Niemann-Pick type C", "GM1-gangliosidosis", "GM1-gangliosidoses", "GM2-gangliosidosis", "GM2-gangliosidoses", "Tay-Sachs disease", "Sandhoff disease", "Krabbe disease", "Metachromatic leukodystrophy", "Multiple-sulfatase deficiency", "Farber disease", "Mucopolysaccharidosis type I", "Mucopolysaccharidosis I", "MPS I", "Hurler syndrome", "Scheie syndrome", "Mucopolysaccharidosis type II", "Mucopolysaccharidosis II", "MPS II", "Hunter syndrome", "Mucopolysaccharidosis type III", "Mucopolysaccharidosis III", "MPS III", "Sanfilippo syndrome", "Mucopolysaccharidosis type IV", "Mucopolysaccharidosis IV", "MPS IV", "MPS IVA", "Morquio syndrome", "Morquio A syndrome", "Mucopolysaccharidosis type VI", "Mucopolysaccharidosis VI", "MPS VI", "Maroteaux-Lamy syndrome", "Mucopolysaccharidosis type VII", "Mucopolysaccharidosis VII", "MPS VII", "Sly syndrome", "Mucopolysaccharidosis type IX", "Mucopolysaccharidosis IX", "MPS IX", "Hyaluronidase deficiency", "Sialidosis", "Galactosialidosis", "Mucolipidosis II", "Mucolipidosis type II", "I-cell disease", "Mucolipidosis III", "Mucolipidosis type III", "Alpha-Mannosidosis", "Alpha-Mannosidase Deficiency", "Beta-Mannosidosis", "Beta-Mannosidase Deficiency", "Fucosidosis", "Aspartylglucosaminuria", "Schindler disease", "Kanzaki disease", "Pompe disease", "Acid lipase deficiency", "Wolman disease", "Cholesterol ester storage disease", "Danon disease", "Free sialic acid storage disease", "Salla disease", "Ceroid lipofuscinosis", "Fabry disease", "Cystinosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-005223-28-DE
(EUCTR)
21/01/201011/08/2009A Study of Eliglustat Tartrate (Genz-112638) in Patients with Gaucher Disease Who Have Reached Thereapeutic Goals with Enzyme Replacement TherapyA Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have reached therapeutic goals with enzyme replacement therapy - ENCORE Gaucher Disease type I
MedDRA version: 18.0;Level: PT;Classification code 10018048;Term: Gaucher's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: Genz-112638
Product Code: Genz-112638
INN or Proposed INN: Eliglustat
Other descriptive name: not available
Product Name: Genz-112638
Product Code: Genz-112638
INN or Proposed INN: Eliglustat
Other descriptive name: not available
Trade Name: Cerezyme
Product Name: Cerezyme
Product Code: imiglucerase
INN or Proposed INN: IMIGLUCERASE
Other descriptive name: Recombinant human derived macrophage-targeted ß-Glucocerebrosidase
Product Name: Genz-112638
Product Code: Genz-112638
INN or Proposed INN: Eliglustat
Other descriptive name: not available
Genzyme Europe B.V.NULLNot RecruitingFemale: yes
Male: yes
150Phase 3United States;Spain;Turkey;Russian Federation;United Kingdom;Italy;Egypt;France;Czech Republic;Canada;Argentina;Brazil;Australia;Netherlands;Germany
2EUCTR2008-005223-28-NL
(EUCTR)
04/11/200901/07/2009A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have Reached Therapeutic Goals with Enzyme Replacement Therapy - ENCOREA Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have Reached Therapeutic Goals with Enzyme Replacement Therapy - ENCORE Gaucher Disease type I
MedDRA version: 9.1;Level: PT;Classification code 10018048;Term: Gaucher's disease
Product Name: Genz-112638
Product Code: Genz-112638
INN or Proposed INN: Eliglustat
Other descriptive name: not available
Trade Name: Cerezyme
Product Name: Cerezyme
Product Code: Imiglucerase
INN or Proposed INN: IMIGLUCERASE
Other descriptive name: Recombinant human derived macrophage-targeted ß-Glucocerebrosidase
Genzyme Europe B.V.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
186Phase 3Czech Republic;Germany;United Kingdom;Netherlands;France;Spain;Italy
3EUCTR2008-005223-28-FR
(EUCTR)
22/10/200905/08/2009A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have been Stabilized with Cerezyme - ENCOREA Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have been Stabilized with Cerezyme - ENCORE Gaucher Disease type I
MedDRA version: 9.1;Level: PT;Classification code 10018048;Term: Gaucher's disease
Product Name: Genz-112638
Product Code: Genz-112638
Trade Name: Cerezyme
Product Name: Cerezyme
Product Code: imiglucerase
INN or Proposed INN: IMIGLUCERASE
Other descriptive name: Recombinant human derived macrophage-targeted ß-Glucocerebrosidase
Genzyme Europe B.V.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
96Phase 3Czech Republic;Germany;United Kingdom;Netherlands;France;Spain;Italy
4EUCTR2008-005223-28-CZ
(EUCTR)
23/09/200921/08/2009A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have Reached Therapeutic goals with Enzyme Replacement Therapy - ENCOREA Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have Reached Therapeutic goals with Enzyme Replacement Therapy - ENCORE Gaucher Disease type I
MedDRA version: 9.1;Level: PT;Classification code 10018048;Term: Gaucher's disease
Product Name: Genz-112638
Product Code: Genz-112638
INN or Proposed INN: Eliglustat tartrate
Other descriptive name: not available
Trade Name: Cerezyme
Product Name: Cerezyme
Product Code: Imiglucerase
INN or Proposed INN: IMIGLUCERASE
Other descriptive name: recombinant human derived macrophage-targeted ß-glucocerebrosidase
Genzyme Europe B.V.NULLNot RecruitingFemale: yes
Male: yes
186Phase 3Germany;United Kingdom;Czech Republic;Netherlands;France;Spain;Italy